Radiotherapy combo superior for intermediate-risk prostate cancer

Combined treatment with intensity-modulated radiotherapy (IMRT) and brachytherapy provides better oncologic outcomes than high-dose IMRT alone in patients with intermediate-risk prostate cancer, researchers concluded in an online report in BJU International.

Renal & Urology News